Listened to the above webinar which mostly went above my head. One thought that was triggered from that discussion is that Race may initiate some work to develop a biomarker tool to identify patients who may benefit from including Zantrene along with the anthracyclines for better cardio-protection. That way it can only be administered to patients who can benefit from it rather than everyone undergoing anthracycline treatments.
As a separate thought, could patients undergoing radiation therapy and at risk of cardio toxicity be given Zantrene for cardio protection?
Ann: Uni of Newcastle Heart Protection Collaboration Extended, page-22
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |